Browse Studies — Arctuva

Phase 4

A Multicenter, Single Arm, Open Label, Pilot Study to Assess the Effect of Atrasentan Alongside Supportive Care on Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy (IgAN)

This multicenter, single-arm, open-label Phase 4 pilot study evaluates the effects of atrasentan added to optimized supportive care on kidney structure and fun…

IgA Nephropathy (IgAN)Immunoglobulin A Nephropathy (IgAN)

Estimated

~$10 – $6,250

University of Illinois at ChicagoNCT07820995

Phase 2

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated ki…

IgANC3GComplement-mediated Kidney Disease+2 more

Estimated

~$10 – $8,750

ADARx Pharmaceuticals, Inc.NCT06989359

Observational

Evaluating the Impact of Autoimmune Protocol Diet on Proteinuria in Patients With IgA Nephropathy

This study at UCLA Center for Health Sciences is testing whether the Autoimmune Protocol (AIP) diet can lower protein levels in the urine of people with IgA Ne…

IgA Nephropathy (IgAN)

Estimated

~$10 – $6,250

University of California, Los AngelesNCT07022574

Phase 2

A Multi-Center, Phase II, Open Label, Randomized Trial Evaluating the Efficacy and Safety of Complement 5a Receptor Antagonist Avacopan in Crescentic IgA Nephropathy

The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic…

IgA Nephropathy (IgAN)

Estimated

~$10 – $6,250

Mayo ClinicNCT06676579